Review



glaucoma induction  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    MedChemExpress glaucoma induction
    Glaucoma Induction, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glaucoma induction/product/MedChemExpress
    Average 92 stars, based on 5 article reviews
    glaucoma induction - by Bioz Stars, 2026-03
    92/100 stars

    Images



    Similar Products

    glaucoma induction  (MedChemExpress)
    92
    MedChemExpress glaucoma induction
    Glaucoma Induction, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glaucoma induction/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    glaucoma induction - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    riluzole hydrochloride  (MedChemExpress)
    92
    MedChemExpress riluzole hydrochloride
    Comparison of intraocular pressure (IOP) measurements of the experimental groups ( n = 7). IOP was measured once a week with a tonometer device. After episcleral vein cauterization, IOP increased to a stable level within 2 weeks. Then, <t>riluzole</t> (5 mg/kg) administration was started simultaneously with the IOP rise. After episcleral vein cauterization, IOP increased in all groups except the control. ** P < 0.001 as compared to the control groups. The data are given as mean ± standard deviation ( n = 7)
    Riluzole Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/riluzole hydrochloride/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    riluzole hydrochloride - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of intraocular pressure (IOP) measurements of the experimental groups ( n = 7). IOP was measured once a week with a tonometer device. After episcleral vein cauterization, IOP increased to a stable level within 2 weeks. Then, riluzole (5 mg/kg) administration was started simultaneously with the IOP rise. After episcleral vein cauterization, IOP increased in all groups except the control. ** P < 0.001 as compared to the control groups. The data are given as mean ± standard deviation ( n = 7)

    Journal: Journal of Current Ophthalmology

    Article Title: Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma

    doi: 10.4103/joco.joco_290_23

    Figure Lengend Snippet: Comparison of intraocular pressure (IOP) measurements of the experimental groups ( n = 7). IOP was measured once a week with a tonometer device. After episcleral vein cauterization, IOP increased to a stable level within 2 weeks. Then, riluzole (5 mg/kg) administration was started simultaneously with the IOP rise. After episcleral vein cauterization, IOP increased in all groups except the control. ** P < 0.001 as compared to the control groups. The data are given as mean ± standard deviation ( n = 7)

    Article Snippet: Riluzole drug administration is started simultaneously with the onset of glaucoma induction, and at the same time every day (12:00–1:00 PM), a single dose of 5 mg/kg/day riluzole hydrochloride (MedChem Express, Cat no. HY-B0211A) is applied.

    Techniques: Comparison, Control, Standard Deviation

    Matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA expression levels of experimental groups. Mean value ± standard deviation ( n = 7). It was determined that MMP-2 and MMP-9 gene expression decreased after riluzole administration compared to the glaucoma group. This decrease was found to be 0.95-fold at the MMP-2 gene level compared to the glaucoma group, and 0.96-fold at the MMP-9 gene level compared to the glaucoma group. **** P < 0.0001 (when compared between control and groups). The data are given as mean ± standard deviation ( n = 7)

    Journal: Journal of Current Ophthalmology

    Article Title: Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma

    doi: 10.4103/joco.joco_290_23

    Figure Lengend Snippet: Matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA expression levels of experimental groups. Mean value ± standard deviation ( n = 7). It was determined that MMP-2 and MMP-9 gene expression decreased after riluzole administration compared to the glaucoma group. This decrease was found to be 0.95-fold at the MMP-2 gene level compared to the glaucoma group, and 0.96-fold at the MMP-9 gene level compared to the glaucoma group. **** P < 0.0001 (when compared between control and groups). The data are given as mean ± standard deviation ( n = 7)

    Article Snippet: Riluzole drug administration is started simultaneously with the onset of glaucoma induction, and at the same time every day (12:00–1:00 PM), a single dose of 5 mg/kg/day riluzole hydrochloride (MedChem Express, Cat no. HY-B0211A) is applied.

    Techniques: Expressing, Standard Deviation, Control

    Hematoxylin-eosin staining of control (A and A1), glaucoma (B and B1), riluzole (C and C1), and DMSO + corn oil (D and D1) groups. No histopathological findings (degeneration in ganglion cells, congestion in vascular structures, hemorrhage, and differentiation in layers) were found in the images (A, C, and D ×10) (A1, C1, and D1 ×20). The glaucoma group differed significantly from the other experimental groups in terms of degeneration in ganglion cells, occlusion in vascular structures, bleeding, and differentiation in layers (B, ×10) (B1, ×20)

    Journal: Journal of Current Ophthalmology

    Article Title: Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma

    doi: 10.4103/joco.joco_290_23

    Figure Lengend Snippet: Hematoxylin-eosin staining of control (A and A1), glaucoma (B and B1), riluzole (C and C1), and DMSO + corn oil (D and D1) groups. No histopathological findings (degeneration in ganglion cells, congestion in vascular structures, hemorrhage, and differentiation in layers) were found in the images (A, C, and D ×10) (A1, C1, and D1 ×20). The glaucoma group differed significantly from the other experimental groups in terms of degeneration in ganglion cells, occlusion in vascular structures, bleeding, and differentiation in layers (B, ×10) (B1, ×20)

    Article Snippet: Riluzole drug administration is started simultaneously with the onset of glaucoma induction, and at the same time every day (12:00–1:00 PM), a single dose of 5 mg/kg/day riluzole hydrochloride (MedChem Express, Cat no. HY-B0211A) is applied.

    Techniques: Staining, Control

    Matrix metalloproteinase-2 (MMP-2) and MMP-9 immunostaining of control (A and A1), glaucoma (B and B1), riluzole (C and C1), and oil + DMSO (D and D1) groups. MMP-2 staining was positive in the glaucoma group (×20)

    Journal: Journal of Current Ophthalmology

    Article Title: Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma

    doi: 10.4103/joco.joco_290_23

    Figure Lengend Snippet: Matrix metalloproteinase-2 (MMP-2) and MMP-9 immunostaining of control (A and A1), glaucoma (B and B1), riluzole (C and C1), and oil + DMSO (D and D1) groups. MMP-2 staining was positive in the glaucoma group (×20)

    Article Snippet: Riluzole drug administration is started simultaneously with the onset of glaucoma induction, and at the same time every day (12:00–1:00 PM), a single dose of 5 mg/kg/day riluzole hydrochloride (MedChem Express, Cat no. HY-B0211A) is applied.

    Techniques: Immunostaining, Control, Staining